S1P modulators such as ceralifimod (selective S1PR1 and S1PR5 modulator), GSK2018682 (selective S1PR-1 and S1PR-5 modulator), and amiselimod (MT-1303) (selective S1PR-1 modulator) have been developed by different drugs companies to treat patients with multiple sclerosis. Here, S1PR1 is linked to multiple sclerosis.